MECOM and cancer: The mechanisms of enhancer deregulation observed in other cancer types, including TAD boundary disruptions and the creation of de novo (super‐) enhancers, may explain overexpression of MECOM or other oncogenes in AML without enhancer hijacking upon translocation.